medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2024, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2024; 22 (2)

Vitiligo: A disease or syndrome

Navarro JBR

Language: Spanish
References: 58
Page: 169-175
PDF size: 128.90 Kb.


ABSTRACT

Vitiligo is worldwide skin dyschromia, it affects all races and ages, with an incidence that varies depending on the population between 1 to 8%, generally accepted between 0.5 to 2%. It is considered a disease, however, in ancient times it was proposed to classify it as a syndrome, with the intention of allowing a better understanding of both concepts, this paper tries to show a general overview of the notions of both terms, with the purpose of understanding the concepts they represent; likewise, we present a brief review of the pathogenesis in vitiligo and its relationship with various conditions.


REFERENCES

  1. Arenas R, Vitiligo. En Arenas R, Dermatología. Atlas, diagnósticoy tratamiento, México, McGraw-Hill, 1992, pp. 108-11.

  2. Saúl A, Discromías. En Saúl A, Lecciones de dermatología, México,Méndez-Cervantes, 1993, pp. 327-44.

  3. Navarro JR, Feria VA y Navarro HQ, El melanocito en el vitíligo,Dermatología Rev Mex 2005; 49(2): 59-68.

  4. Surós BA, Generalidades. En Surós BA, Semiología médicay técnica exploratoria, Barcelona, Elsevier Masson, 2001, pp.1-62.

  5. Real Academia Nacional de Medicina de España, Diccionario detérminos médicos, 2012. Consultado en abril de 2023. Disponibleen: https: //dtme.ram.es/index.aspx.

  6. Dabaut E, Diccionario de medicina, reed., México, Época, 1999,p. 245.

  7. Hierro OS, Glosario dermatológico, 1ª ed., México, Wellcome,1995, p. 158.

  8. Pérez TR, coda. En Pérez TR, Enfermedades viejas y enfermedadesnuevas, México, Siglo XXI Editores, 1985, pp. 163-64.

  9. Sigerist HE, La higiene de Galeno. En Sigerist HE, Hitos en lahistoria de la salud pública, México, Siglo XXI Editores, 1981,pp. 13-34.

  10. Dabaut E, Diccionario de medicina, reed., México, Época, 1999,p. 588.

  11. Le Poole IC, Van den Wijngaard RM, Westerhof W y Das PK,Pesence of t cells and macrophages in inflamatory vitiligoskin parallels melanocyte disappereace, Am J Pathol 1996;148:1219-28.

  12. Frisoli ML, Essien K y Harris JE, Vitiligo: mechanisms of pathogenesisand treatment, Annu Rev Immunol 2020; 38:621-48.

  13. Kemp EH, Emhemad S, Akhtar S, Watson PF, Gawkrodger DJ,Weetman AP, Autoantibodies against tyrosine hydroxylase in patientswith non-segmental (generalised) vitiligo, Exp Dermatol2011; 20(1):35-40.

  14. Song YH, Connor E, Li Y, Zorovich B, Balducci P y MaclarenN, The role of tyrosinase in autoimmune vitiligo, Lancet 1994;344(8929):1049-52.

  15. Baharav E, Merimski O, Shoenfeld Y et al., Tyrosinase as anautoantigen in patients with vitiligo, Clin Exp Immunol 1996;105(1):84-8.

  16. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF y WeetmanAP, Autoantibodies to tyrosinase-related protein-1 detectedin the sera of vitiligo patients using a quantitative radiobindingassay, Br J Dermatol 1998; 139(5):798-805.

  17. Park YK, Kim NS, Hann SK, Im S, Identification of autoantibodyto melanocytes and characterization vitiligo antigen in vitiligopatients, J Dermatol Sci 1996; 11:111-20.

  18. Cui J, Arita Y y Bystryn JC, Charecterization of vitiligo antigens,Pigment Cell Res 1995; 8:53-9.

  19. Arenas R, Vitiligo. En Arenas R, Dermatología. Atlas, diagnósticoy tratamiento, México, McGraw-Hill Interamericana, 2015,pp. 125-31.

  20. Spritz RA y Andersen GHL, Genetics of vitiligo, Dermatol Clin2017; 35(2):245-55.

  21. Foley LM, Lowe NJ, Misheloff E y Tiwari JL, Association of hladr4with vitiligo, J Am Acad Dermatol 1983; 8:30-40.

  22. Finco O, Ciccia M, Martinelti M et al., Age of onset in vitiligo:relationship hla supratypes, Clin Genet 1991; 39:48-50.

  23. Casp CB, She JX y McCormack WT, Genes of the lmp/tap clusterare associated with the human autoimmune disease vitiligo,Genes Immun 2003; 4:492-9.

  24. Unal A, Ozkol HU, Bayram Y y Akdeniz N, Comparison of tyrosinaseantibody, tyrosinase-related protein-1 and -2 antibodies,melanin-concentrating hormone receptor antibody levels withautologous serum skin test and autologous plasma skin testresults in patients with vitiligo, Postepy Dermatol Alergol 2021;38(3):473-9.

  25. Salzer BA y Schallreuter KU, Investigation of the personalitystructure in patients with vitiligo and a possible associationwith impaired catecholamine metabolism, Dermatology 1995;190:109-15.

  26. Matoo SK, Handa S, Kaur I, Gupta N y Malhotra R, Psychiatricmorbidity in vitiligo: prevalence and correlates in India, J EurAcad Dermatol Venereol 2002; 16:573-8.

  27. Papadopoulos L, Bor R, Legg C y Hawk JI, Impact of life eventson the onset of vitiligo in adults: preliminary evidence for psychologicaldimension in a etiology, Clin Exp Dermatol 1998; 23:243-8.

  28. Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari Py Handjani F, Evaluating prevalence of depression, anxiety andhopelessness in patients with vitiligo on an Iranian population,Health Qual Life Outcomes 2020; 18(1):20.

  29. Koshevenko LN, The psychological characteristics of patientswith vitiligo, Vestn Dermatol Venerol 1989; 5:4-6.

  30. Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, DellatorreG y Miot HA, Update on the pathogenesis of vitiligo, AnBras Dermatol 2022; 97(4):478-90.

  31. Chang WL y Ko CH, The role of oxidative stress in vitiligo: anupdate on its pathogenesis and therapeutic implications, Cells2023; 12(6):936.

  32. Dammak I, Boudaya S, Abdallah FB, Turki H, Attia H y Hentati B,Antioxidant enzymes and lipid peroxidation at the tissue levelin patients with stable and active vitiligo, Int J Dermatol 2009;48(5):476-80.

  33. Bialczyk A, Welniak A, Kaminska B y Czajkowski R, Oxidativestress and potential antioxidant therapies in vitiligo: a narrativereview, Mol Diagn Ther 2023; 27(6):723-39.

  34. Kokoszko DW, Lukasik K, Szepietowski JC et al., Assessmentof stem cell factor expression and its c-kit receptor in patientswith vitiligo, Postepy Dermatol Alergol 2022; 39(4):762-7.

  35. Moretti S, Spallanzani A, Amato L et al., New insights into thepathogenesis of vitiligo: imbalance of epidermal cytokines atsites of lesions, Pigment Cell Res 2002; 15: 87-92.

  36. Navarro JR, Canales AA, Salado PH y Feria VA, Mini injerto autólogode piel e ingestión de 8-metoxipsoraleno en pacientes convitíligo vulgar estable, Dermatología Rev Mex 2002; 46:260-7.

  37. Navarro JR, Canales AA, Salado PH y Feria VA, Cantidad demelanocitos que se forman en el vitíligo vulgar estable utilizandocinco modalidades de tratamiento, Patología 2005;43(3):142-50.

  38. Caxia T, Hongwen F y Xiran L, Levels of soluble interleukin-2 receptorin the sera and skin tissue fluids of patients with vitiligo,J Dermatol Sci 1999; 21:59-62.

  39. Wu CS, Yu HS, Chang HR, Yu CL y Wu BN, Cutaneous bloodflow and adrenoreceptor response increase in segmental typevitiligo lesions, J Dermatol Sci 2000; 23:53-62.

  40. Lazarova R, Hristakieva E, Lazarova N y Shani J, Vitiligo-relatedneuropeptides in nerve fibers of the skin, Arch Physiol Biochem2000; 108:262-7.

  41. Cucchi ML, Frattini P, Santagostino G y Orecchia G, Higher plasmacatecholamine and metabolite levels in the early phase ofnonsegmental vitiligo, Pigment Cell Res 2000; 13:28-32.

  42. Cucchi ML, Frattini P, Santagostino G, Preda S y Orecchia G, Catecholaminesincrease in the urine of non-segmental vitiligo especiallyduring its active pas, Pigment Cell Res 2003; 16(2):111-6.

  43. Taieb A, Intrinsic and extrinsic pathomechanisms in vitiligo, PigmentCell Res 2000; 13 Suppl 8:41-7.

  44. Dell’Anna ML, Maresca V, Briganti S, Camera E, Falchi M y PicardoM, Mitochondrial impairment in peripheral blood mononuclearcells during the active phase of vitiligo, J Invest Dermatol2001; 117:908-13.

  45. Boissy RE, Liu YY, Medrano EE y Nordlund JJ, Structural aberrationof the rough endoplasmic reticulum and melanosome compartmentalizationin long-term cultures of melanocytes fromvitiligo patients, J Invest Dermatol 1991; 97(3):395-404.

  46. Jadeja SD, Mayatra JM, Vaishnav J, Shukla N y Begum R, A concisereview on the role of endoplasmic reticulum stress in thedevelopment of autoimmunity in vitiligo pathogenesis, FrontImmunol 2021; 11:624566.

  47. Zhang X, Lei L, Jiang L et al., Characteristics and pathogenesisof Koebner phenomenon, Exp Dermatol 2023; 32(4):310-23.

  48. Khurrum H, Alghamdi KM, Bedaiwi KM y Albalahi NM, Multivariateanalysis of factors associated with the Koebner phenomenonin vitiligo: an observational study of 381 patients, AnnDermatol 2017; 29(3):302-6.

  49. Njoo MD, Das PK, Bos JD y Westerhof W, Association of the Koebnerphenomenon with disease activity and therapeutic responsivenessin vitiligo vulgaris, Arch Dermatol 1999; 135:407-13.

  50. Hatchome N, Kato T y Tagamani H, Therapeutic success of epidermalgrafting in generalized vitiligo is limited by Koebner phenomenom,J Am Acad Dermatol 1990; 22:87-91.

  51. Huang CL, Nordlund JJ y Boissy R, Vitiligo: a manifestation ofapoptosis?, Am J Clin Dermatol 2002; 3(5):301-8.

  52. Srivastava N, Gupta S y Parsad D, Melanocyte adhesion andapoptosis in vitiligo: linking puzzle blocks, Curr Mol Med 2023;23(8):709-11.

  53. Ruiz AA, Jiménez BG, Reyes IP, Pérez RB y Sánchez SS, Apoptosisof melanocytes in vitiligo results from antibody penetration,J Autoimmun 2007; 29(4):281-6.

  54. Bakry AO, Hammam AM y Wahed MAM, Immunohistochemicaldetection of P53 and Mdm2 in vitiligo, Indian Dermatol OnlineJ 2012; 3(3):171-6.

  55. Laddha CN, Dwivedi M, Mansuri MS et al., Vitiligo: interplaybetween oxidative stress and immune system, ExperimentalDermatology 2013; 22:245-50.

  56. Lee HJ, Ju HJ, Seo JM et al., Comorbidities in patients with vitiligo.A systematic review and meta-analysis, J Invest Dermatol2023; 143:777-89.

  57. Taylor Ch y Taneja A, Vitíligo y síndromes asociados. En TorresLV, Camacho MF, Mihm MC, Sober AJ y Sánchez CI, Dermatologíapráctica iberolatinoamericana. Atlas, enfermedades sistémicasasociadas y terapéutica, México, Nieto Editores, 2005,pp. 705-18.

  58. Chávez AJF, Cortez VLC, Basurto MM y Sarango CAF, Vitíligo,diagnóstico y tratamiento, Reciamuc 2023; 7(1):187-95.




2020     |     www.medigraphic.com